Krystal Biotech

Edit info

Founded: 2015

Location: Pittsburgh, PA

Employee range: 50 - 200

Clinical stage: Clin3

Therapy area: Dystrophic epidermolysis bullosa (ODD, Fast track)

Drug types: DRM, RAR, GEN, PED, AES, LNG

Lead product: B-VEC

Funding: $160M stock May 2023

krystalbio.com

linkedin.com

job board

Drug notes:

KB105 Clin1/Clin2 TGM1-deficient ARCI (ODD, fast track); KB407 Clin1 cystic fibrosis (ODD); KB301 Clin1 undisclosed; KB104 Clin0 Netherton syndrome; KB5XX Clin0 skin conditions; KB408 Clin0 alpha-1 antitrypsin deficiency; 6+ additional programs RD/Clin0 undisclosed

About:

Krystal Biotech is developing gene therapies to address skin diseases. Many debilitating skin diseases lack effective treatments. Krystal is solving this by introducing therapeutic genes into patients with skin diseases. To achieve this, Krystal is using their patented gene therapy platform, Skin TARgeted Delivery (STAR-D), that consists of an engineered HSV-1 vector optimized for gene transfer in skin. The engineered HSV-1 vector is replication-defective and non-integrating such that it can penetrate a broad range of skin cells without posing a risk to genome disruption. The therapies are designed to be administered topically allowing direct and repeat delivery of therapeutic genes to the skin. Krystal’s most advanced therapy for Epidermolysis Bullosa is in Phase 3 trials.